Latest Breaking News On - Bymatthew shinkle - Page 1 : vimarsana.com

Glucose-lowering drugs reduce risk for obesity-related cancers

CHICAGO — Glucagon-like peptide-1 receptor agonists lowered the risk for obesity-related cancers compared with bariatric surgery among individuals with a BMI of at least 35, according to data presented at ASCO Annual Meeting. Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) conferred a greater risk reduction in all-cause mortality, despite inferior weight loss results

Al-assisted navigation increases referrals for suspected pancreatic cancer

CHICAGO — An AI-guided navigation workflow helped identify patients earlier in the diagnostic timeline than the traditional cancer referral process while reducing times to biopsy, follow-up and treatment initiation, study results showed. Researchers, who presented their findings at ASCO Annual Meeting, also noted that implementation of the AI-guided navigation workflow increased patient

Keytruda extends survival in high-risk triple negative breast cancer

A study assessing the efficacy of pembrolizumab met a key secondary endpoint of extending OS, in combination with chemotherapy, among patients with high-risk early-stage triple-negative breast cancer, according to the agent’s manufacturer. Pembrolizumab (Keytruda, Merck), an anti-PD-1 therapy, has two approved indications for triple-negative breast cancer.

Active cancer treatment linked to increased risk for sudden cardiac arrest

Active cancer treatment is associated with increased risk for sudden cardiac death, especially among patients younger than 74 years old and those with a history of heart failure, results from a retrospective study showed. The findings, published in The American Journal of Cardiology, indicated that patients who harbored multiple risk factors had a significantly higher probability of sudden

Metformin use linked to lower risk for rare blood cancer

Individuals prescribed the antidiabetes treatment metformin less likely developed a myeloproliferative neoplasm —potentially also reducing a person’s chances for developing certain cancers — according to data published in Blood Advances.Metformin is a therapy used by patients with type 2 diabetes to treat high blood sugar by increasing the efficacy of insulin.

Immune-related toxicity from immune checkpoint inhibitors linked to longer survival

Setanaxib-pembrolizumab combination extends survival in advanced head and neck cancer

Breast cancer survivors benefit from heart-healthy diet

Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint

'Substantial geographic disparities' worsening in cancer clinical trial availability